Skip to main content
. 2019 Dec 16;21:143. doi: 10.1186/s13058-019-1210-4

Table 1.

Study outcomes of TNBC patients treated with NCCN-recommended (v1.2016) monotherapy and combination therapy

Author Study description Treatment Patient population % 1L % 2L % 3L+ N ORR % DOR, months PFS, months OS, months % TNBC patients
NCCN-recommended (v1.2016) monotherapies
 Aftimos et al. [23] Retrospective phase III sub-group analysis Eri 2L+ MBC w/mTNBC 0 100 22 18 N/R N/R N/R 17
 Awada et al. [24] Phase II Pac 1L mTNBC 100 0 0 28 28.6 N/R 3.5 13.1 100
 Baselga et al. [25] Phase II Cis 1L–2L mTNBC 72 28 0 60 10 N/R 1.5 9.4 100
Phase II Cis 1L mTNBC 42 12 N/R N/R N/R 100
Phase II Cis 2L mTNBC 16 6 N/R N/R N/R 100
 Brufsky et al. [26] RIBBON-2 Physician’s choice chemo 2L MBC w/mTNBC 0 100 0 47 18 N/R 2.7 12.6 21
 Isakoff et al. [27] Phase II Car/cis 1L–2L mTNBC 80 20 0 86 25.6 N/R 2.9 11 100
Phase II Car/cis 1L mTNBC 69 29 N/R N/R N/R 100
Phase II Car/cis 2L mTNBC 17 11.8 N/R N/R N/R 100
 Miles et al. [28] RIBBON-1 + AVADO + E2100 pooled subgroup Cap/doc/pac 1L MBC w/mTNBC 100 0 0 255 23.3 N/R 5.4 17.5 26
 Perez et al. [29] BEACON Physician’s choice chemo 3L+ MBC w/mTNBC 0 0 100 117 N/R N/R N/R 8.8 28
 Pivot et al. [30] Prespecified phase III subgroup Cap 1L–3L+ MBC w/mTNBC 9 49 43 96 9 N/R 2.1 N/R 25
 Sparano et al. [31] Phase III Cap 1L–3L+ MBC w/mTNBC 19 63 18 134 N/R N/R 1.81 N/R 22
 Study 301 Phase III subgroup Cap 1L MBC w/mTNBC 40 12 4.4 N/R 9.9 24.5
Eri 1L MBC w/mTNBC 40 10.4 6.6 N/R 13.1 27.1
Phase III subgroup Cap 2L+ MBC w/mTNBC 96 ~ 10 5.9 2.8 9.2 24.5
Eri 2L+ MBC w/mTNBC 110 ~ 10 4.2 3.4 15.2 27.1
 Tredan et al. [32] Phase II Ixa 1L mTNBC 100 0 0 40 30 4.5 4.1 N/R 100
 Twelves et al. [9] and Pivot et al. [13] EMBRACE + 301 pooled subgroup Eri 1L–3L+ MBC w/mTNBC 11 27 62 243 12 N/R 2.8 12.9 22.9
EMBRACE + 301 pooled subgroup Eri 2L+ MBC w/mTNBC 199 11 N/R 2.8 12.4 22.9
 Twelves et al. [9] and Pivot et al. [13] EMBRACE + 301 pooled subgroup Physician’s choice chemo 1L–3L+ MBC w/mTNBC 13 37 50 185 10.3 N/R 2.6 8.2 23.1
EMBRACE + 301 pooled subgroup Physician’s choice chemo 2L+ MBC w/mTNBC 153 9 N/R 2.5 8.1 23.1
 von Minckwitz et al. [33] TANIA Physician’s choice chemo 2L MBC w/mTNBC 0 100 0 57 N/R N/R 2.1 N/R 23
NCCN-v1.2016-recommended combination therapies
 Brodowicz et al. [34]§ TURANDOT Bev+pac 1L MBC w/mTNBC 100 0 0 63 49 N/R 9 24.2 22
 Dieras et al. [35] Phase II Bev+pac 1L–2L mTNBC 81 19 0 61 47.53 7.5 7.2 17.4 100
Phase II Bev+pac 1L mTNBC 46 N/R N/R 7.2 N/R 100
Phase II Bev+pac 2L mTNBC 16 N/R N/R 7 N/R 100
 Fan et al. [36] Phase II Doc+cap 1L mTNBC 100 0 0 26 15.4 N/R 4.8 21.5 100
 Halim et al. [37] Phase II Car+pac 2L+ mTNBC 0 100 50 60 N/R N/R N/R 100
 Li et al. [38] Phase II Cap+cis 1L–3L mTNBC 84.9 12.1 3 33 63.6 N/R 8.2 17.8 100
Phase II Cap+cis 1L mTNBC 28 64.3 N/R 8.2 19.6 100
Phase II Cap+cis 2L–3L mTNBC 5 60 N/R 5.1 16.5 100
 Liao et al. [39] Phase II Doc+cap 1L mTNBC 100 0 0 27 14.8 N/R 4.9 21.5 100
 Liao et al. [39] Phase II Vin+cap 1L mTNBC 100 0 0 18 27.8 N/R 5.2 18.2 100
 Miles et al. [28]* (many combinations with high ORR—OS is still not much higher) Pooled phase III (E2100, AVADO, RIBBON-1) Bev+(cap/doc/pac/nab-pac/(dox/epi/CP/ FU)) 1L MBC w/mTNBC 100 0 0 360 42.3 N/R 8.1 18.9 25
 O’Shaughnessy et al. [40] Phase III Gem+car 1L–3L mTNBC 58 42 244 32 N/R 4.1 11.1 100
Phase III Gem+car 1L mTNBC 149 N/R N/R 4.6 13.9 100
Phase III Gem+car 2L–3L mTNBC 109 N/R N/R 2.9 8.1 100
 Pivot et al. [30] Prespecified phase III subgroup Ixa+cap 1L–3L+ MBC w/mTNBC 7 48 45 91 27 N/R 4.1 N/R 24.3
 Rugo et al. [41] Phase III Bev+nab-pac 1L MBC w/mTNBC 100 0 0 65 N/R N/R 7.4 N/R 24
 Rugo et al. [41] Phase III Bev+ixa 1L MBC w/mTNBC 100 0 0 63 N/R N/R 5.6 N/R 26
 Rugo et al. [41] Phase III Bev+pac 1L MBC w/mTNBC 100 0 0 73 N/R N/R 6.5 N/R 26
 Sparano et al. [31] Phase III Ixa+cap 1L–3L+ MBC w/mTNBC 20 61 19 122 N/R N/R 4.2 N/R 20

1L first-line, 2L second-line, 3L third-line, APaT all patients as treated, Bev bevacizumab, Cap capecitabine, Car carboplatin, chemo chemotherapy, Cis cisplatin, CP cyclophosphamide, Doc docetaxel, Dox doxorubicin, Epi epirubicin, Eri eribulin, FU fluorouracil, Gem gemcitabine, Ixa ixabepilone, MBC metastatic breast cancer, mTNBC metastatic triple-negative breast cancer, N/R not reported, ORR objective response rate, Pac paclitaxel, TNBC triple-negative breast cancer, Vin vinorelbine

*Paclitaxel in E2100, docetaxel in AVADO, capecitabine in one cohort of RIBBON-1, and either a single-agent taxane or an anthracycline-based combination in the second cohort of RIBBON-1. Of the total n = 255 in the meta-analysis, n = 46 belong to the taxane/anthracycline cohort of RIBBON-1; the number (< 46) of this subset of patients receiving anthracycline combination is unknown

Based on internal communication with trial sponsor (Eisai); not published results

n and ORR based on APaT population

§2L+ MBC with mTNBC outcomes are available in a separate study from Pivot et al. [13]